WO2021033995A1 - Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie - Google Patents

Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie Download PDF

Info

Publication number
WO2021033995A1
WO2021033995A1 PCT/KR2020/010685 KR2020010685W WO2021033995A1 WO 2021033995 A1 WO2021033995 A1 WO 2021033995A1 KR 2020010685 W KR2020010685 W KR 2020010685W WO 2021033995 A1 WO2021033995 A1 WO 2021033995A1
Authority
WO
WIPO (PCT)
Prior art keywords
excess
extract
muscle
amomum tsaoko
active ingredient
Prior art date
Application number
PCT/KR2020/010685
Other languages
English (en)
Korean (ko)
Inventor
최정호
이종영
박지훈
Original Assignee
고려제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려제약주식회사 filed Critical 고려제약주식회사
Publication of WO2021033995A1 publication Critical patent/WO2021033995A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants

Definitions

  • the present invention relates to the prevention and / or alleviation and / or treatment of diseases related to muscle loss containing a herbal ingredient, specifically, for the prevention and / or treatment of diseases related to muscle loss comprising an excess (Amomum Tsaoko) extract It provides a pharmaceutical composition, and a food composition for preventing and/or improving muscle loss-related diseases.
  • Skeletal muscle is an organ that occupies the largest part of the human body and accounts for 40-50% of the total body weight, and plays an important role in various metabolic functions in the body, including energy homeostasis and heat generation.
  • Human muscles decrease by more than 1% every year after age 40. Particularly, at the age of 80, it is reduced to 50% of the maximum muscle mass, and this loss of muscle in old age is the most important factor in reducing overall physical function.
  • the body shape changes such as muscle and fat content and skeletal distortion, and the prevalence of obesity due to muscle loss in old age continues to increase at a level of over 30% worldwide.
  • sarcopenia In the case of abnormal insulin secretion, it can cause muscle development disorders due to the inability to properly supply energy to the cells, resulting in increased muscle loss in diabetics than in the general population. In addition, a decrease in muscle is a cause of further increase in arthritis, back pain, and chronic pain, and may worsen symptoms of urinary incontinence caused by abdominal obesity, and may increase the fracture rate. As such, sarcopenia, especially in older age, is associated with various diseases and is a major cause of poor quality of life. It is known that sarcopenia is also closely related to senile chronic diseases such as osteoporosis, insulin resistance, and arthritis, and it is possible to suppress a decrease in physical activity due to aging through the prevention or improvement of sarcopenia.
  • One example provides a pharmaceutical composition for the prevention and/or treatment of diseases related to muscle loss comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for inhibiting muscle loss or increasing muscle, including excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for promoting muscle cell generation and/or differentiation comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for enhancing muscle movement ability, including the excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for treating muscle fatigue comprising an excess (Amomum Tsaoko ) extract as an active ingredient.
  • Another example provides a medium composition for muscle cell proliferation and/or differentiation comprising an excess (Amomum Tsaoko) extract.
  • Another example provides a food composition for preventing and/or ameliorating diseases related to muscle loss, comprising an excess (Amomum Tsaoko) extract.
  • Another example provides a food composition for inhibiting muscle loss or increasing muscle mass, comprising an extract of Amomum Tsaoko.
  • Another example provides a food composition for promoting differentiation (production) of muscle cells comprising an extract of Amomum Tsaoko.
  • Another example provides a food composition for improving muscle motor ability, comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a food composition for improving muscle fatigue comprising an excess (Amomum Tsaoko ) extract as an active ingredient.
  • Another example provides a food composition for enhancing mitochondrial function comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a method of preventing and/or treating a disease related to muscle loss, comprising administering an effective amount of an excess (Amomum Tsaoko) extract to a subject in need thereof.
  • Another example provides a method of inhibiting muscle loss or increasing muscle mass, comprising administering an effective amount of an excess ( Amomum Tsaoko) extract to a subject in need thereof.
  • Another example provides a method of promoting muscle cell proliferation, production and/or differentiation comprising administering an effective amount of an excess ( Amomum Tsaoko) extract to a subject in need thereof.
  • Another example provides a method for enhancing or improving muscle motor ability, comprising administering an effective amount of an excess ( Amomum Tsaoko) extract to a subject in need thereof.
  • Another example provides a method of treating or ameliorating muscle fatigue, comprising administering an effective amount of an excess (Amomum Tsaoko ) extract to a subject in need of treatment or improvement of muscle fatigue.
  • Another example provides a food composition for enhancing mitochondrial function, comprising an effective amount of excess (Amomum Tsaoko) extract as an active ingredient for enhancing mitochondrial function.
  • Another example provides a method for differentiation, proliferation, and/or production of myoblasts, comprising culturing myoblasts with an extract of Amomum Tsaoko.
  • the excess ( Amomum Tsaoko ) extract promotes muscle cell proliferation, muscle cell production and/or differentiation, and has excellent phosphorylation effects of AKT and mTOR, enhances muscle motor ability, promotes root canal differentiation, enhances mitochondrial function, and improves muscle fatigue. It was confirmed to have an effect.
  • the use of the excess ( Amomum Tsaoko ) extract to inhibit muscle loss, promote muscle cell production and/or differentiation, and prevent/treat diseases related to muscle loss is provided.
  • a pharmaceutical composition for the prevention and/or treatment of diseases related to muscle loss comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • a pharmaceutical composition for inhibiting muscle loss or increasing muscle comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • a pharmaceutical composition for promoting muscle cell generation and/or differentiation comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for enhancing muscle movement ability, including the excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a pharmaceutical composition for treating muscle fatigue comprising an excess (Amomum Tsaoko ) extract as an active ingredient.
  • Another example provides a medium composition for muscle cell proliferation and/or differentiation comprising an excess (Amomum Tsaoko) extract.
  • a food composition for preventing and/or ameliorating a disease related to muscle loss comprising an excess (Amomum Tsaoko) extract is provided.
  • a food composition for inhibiting muscle loss or increasing muscle comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • a food composition for promoting muscle cell production and/or differentiation comprising an excess (Amomum Tsaoko) extract is provided.
  • Another example provides a food composition for improving muscle motor ability, comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • Another example provides a food composition for improving muscle fatigue comprising an excess (Amomum Tsaoko ) extract as an active ingredient.
  • Another example provides a food composition for enhancing mitochondrial function comprising an excess (Amomum Tsaoko) extract as an active ingredient.
  • a method of preventing and/or treating a muscle loss-related disease comprising administering an effective amount of an excess (Amomum Tsaoko) extract to a subject in need thereof.
  • a method of inhibiting muscle loss or increasing muscle comprising administering an effective amount of an excess (Amomum Tsaoko) extract to a subject in need thereof.
  • a method for promoting muscle cell generation and/or differentiation comprising administering an effective amount of an excess (Amomum Tsaoko) extract to a subject in need of promoting muscle cell production and/or differentiation.
  • Another example provides a method for enhancing or improving muscle motor ability, comprising administering an effective amount of an excess ( Amomum Tsaoko) extract to a subject in need thereof.
  • Another example provides a method of treating or ameliorating muscle fatigue, comprising administering an effective amount of an excess (Amomum Tsaoko ) extract to a subject in need of treatment or improvement of muscle fatigue.
  • Another example provides a food composition for enhancing mitochondrial function, comprising an effective amount of excess (Amomum Tsaoko) extract as an active ingredient for enhancing mitochondrial function.
  • Another example provides a method for differentiation, proliferation, and/or production of myoblasts, comprising culturing myoblasts with an extract of Amomum Tsaoko.
  • the myoblasts may be mammalian.
  • the myoblast cells may be isolated from the human body.
  • the step of culturing may be performed by culturing in a medium containing an extract of excess myoblast (Amomum Tsaoko).
  • Excess (Amomum Tsaoko ) extract included or used as an active ingredient in the pharmaceutical composition, food composition and/or method provided herein is extracted with an extraction solvent by extracting excess outpost or part (eg, fruit, etc.) It may be an extract obtained.
  • the excess or part (eg, fruit) of the above can be used for extraction as it is or in a dried and/or heated state.
  • the extraction solvent may be water, a lower alcohol (a linear or branched alcohol having 1 to 4 carbon atoms, such as ethanol), or a mixture thereof, for example, 30 to 100% (v/v), 50 to 100% ( v/v), 60 to 100% (v/v), 62 to 100% (v/v), 64 to 100% (v/v), 65 to 100% (v/v), 66 to 100% ( v/v), 67 to 100% (v/v), 68 to 100% (v/v), 69 to 100% (v/v), or 70 to 100% (v/v) of lower alcohol or lower It may be an aqueous alcohol solution (eg, ethanol or an aqueous ethanol solution).
  • a lower alcohol a linear or branched alcohol having 1 to 4 carbon atoms, such as ethanol
  • a mixture thereof for example, 30 to 100% (v/v), 50 to 100% ( v/v), 60 to 100% (v/v), 62 to 100% (v/v), 64 to 100% (v/v), 65 to 100% (v/v
  • the amount of the extraction solvent used for the extraction is at least 2 times by volume (e.g., excess (dried) grass and/or part) based on the weight of the excess grass and/or part, such as the dry weight of the grass and/or part. It means that it is 2L or more based on 1kg), 5 times by volume, 7 times by volume, or 10 times by volume, but is not limited thereto.
  • the extraction may be carried out once, or two or more times (eg, two times, three times, four times, or five times) with the same or different extraction solvents and/or conditions.
  • the extraction time is not limited thereto, but 1 to 48 hours, 1 to 36 hours, 1 to 24 hours, 1 to 12 hours, 1 to 6 hours, 3 to 48 hours, 3 to 36 hours for sufficient extraction of the active ingredient , 3 to 24 hours, 3 to 12 hours, or 3 to 6 hours.
  • the extraction time per each time may be within the above range, but is not limited thereto.
  • the extraction temperature is not limited thereto, but for effective extraction of the active ingredient, from room temperature to the boiling point of the extraction solvent (eg, 15 to 100°C, 20 to 100°C, 25 to 100°C, 30 to 100°C, 35 to 100°C , 40 to 100°C, 45 to 100°C, 50 to 100°C, 55 to 100°C, 60 to 100°C, 65 to 100°C, 70 to 100°C, 75 to 100°C, 80 to 100°C, 85 to 100°C , 90 to 100 °C, 95 to 100 °C, 97 to 100 °C, 15 to 97 °C, 20 to 97 °C, 25 to 97 °C, 30 to 97 °C, 35 to 97 °C, 40 to 97 °C, 45 to 97 °C , 50 to 97°C, 55 to 97°C, 60 to 97°C, 65 to 97°C, 70 to 97°C, 75 to 97°C, 80 to 97°C, 15
  • the extraction method for obtaining the extract can be prepared according to a known extraction method commonly used in the art to which the present invention belongs. Specifically, commonly used extraction methods such as reflux extraction, immersion extraction, heat extraction, cold precipitation, hot water extraction, ultrasonic extraction, filtration, pressure extraction, supercritical extraction, and electric extraction may be used.
  • the excess extract is immersed in water or 50 to 100% (v / v) ethanol (or 70 to 100% (v / v) ethanol) (15 to 25 °C) or 70 to 95 It may be obtained by reflux extraction at °C temperature.
  • the term'muscle loss-related disease' may refer to a disease selected from all symptoms related to muscle loss and all diseases caused thereby, or a symptom of the disease.
  • the muscle loss may be caused by aging, but is not limited thereto.
  • the muscle loss-related disease may be one or more diseases selected from the group consisting of sarcopenia, muscular dystrophy, muscular dystrophy, dystonia, myasthenia gravis, and the like, and may be, for example, sarcopenia.
  • Sarcopenia refers to a symptom of gradually decreasing skeletal muscle mass with aging or a disease resulting from a certain factor, such as aging, and directly causes a decrease in muscle strength, and as a result, decreases in various body functions and /Or it could mean a pathological condition that could cause a disability.
  • Muscular atrophy is the progressive degeneration of motor nerve fibers and cells in the spinal cord, as the muscles of the limbs are gradually atrophy, causing amyotrophic lateral sclerosis (ALS) and/or progressive spinal cord. It can cause spinal progressive muscular atrophy (SPMA).
  • the muscular dystrophy may be age-related muscular atrophy or obese muscular atrophy.
  • The'aging muscular dystrophy' is a chronic low-stage inflammation in which gradual loss of muscle mass and/or muscle strength due to aging and/or an increase in visceral fat and accompanying inflammation-causing cytokines increase. It may be caused by chronic low-grade inflammation.
  • The'obesity muscular dystrophy' refers to a phenomenon in which obesity, such as obesity in old age, further aggravates the muscle loss, and fat is deposited in the muscle due to obesity, thereby reducing muscle mass and increasing mast cell-derived inflammatory factors,
  • obesity such as obesity in old age
  • fat is deposited in the muscle due to obesity, thereby reducing muscle mass and increasing mast cell-derived inflammatory factors
  • the function of the mitochondria in the muscle is deteriorated, the function of the muscle is further weakened, and if an abnormality in the secretion of insulin occurs due to obesity, it may be caused by impairment of muscle development because the energy cannot be properly supplied to the cells.
  • Muscular dystrophy also known as muscular dystrophy, is a disease in which gradual muscle atrophy and muscle weakness appear, and is one of the degenerative myopathy characterized by necrosis of muscle fibers in pathology.
  • Atony is also called hypotonia, and may mean a condition in which muscle tension is reduced or lost, or a pathological condition resulting from it.
  • muscle tension is also regulated by reflexes. When this control function is destroyed, it may be a disease caused by an increase or loss of tension.
  • Myasthenia is a disease in which the contractile power of the muscles decreases and the muscles are easily fatigued and loses strength.There are vasosclerotic myasthenia, gastric myasthenia, and myasthenia gravis, which can generally mean myasthenia gravis. .
  • Myasthenia gravis is a disease caused by a neurotransmission disorder at the neuromuscular junction, and may show pathological findings of a change in the morphology of the post-synaptic membrane at the neuromuscular junction and a decrease in the number of nicotinic acetylcholine receptors.
  • 'treatment' includes all of the improvement, alleviation or stabilization of a disease state or symptom, partial or complete recovery, prolongation of survival, reduction of the disease range, delay or alleviation of disease progression, and other beneficial treatment results.
  • 'Prevention' is used as a meaning to include all mechanisms and/or effects that act on a subject who does not have a specific disease to prevent the onset of the specific disease, delay the onset of the disease, or reduce the frequency of onset.
  • improving or improving muscle motor capability may mean recovery and/or improvement of lost or decreased muscle motor capability, and/or strengthening of muscle motor capability.
  • mitochondrial function enhancement may mean strengthening mitochondrial function of muscle cells, and mitochondrial function enhancement may be due to increased mitochondrial biosynthesis, and/or mitochondrial antioxidant activity (reduction or elimination of mitochondrial active oxygen). I can.
  • the content of the excess extract used as an active ingredient in the pharmaceutical composition can be appropriately adjusted according to the form and purpose of use, the condition of the object to be used, the type and severity of symptoms, etc. 0.001 to 99.9 wt%, 0.001 to 90 wt%, 0.001 to 75 wt%, 0.001 to 50 wt%, 0.01 to 99.9 wt%, 0.01 to 90 wt%, 0.01 to 75 wt%, 0.01 to 50 wt%, 0.1 to 99.9 wt%, 0.1 to 90 wt%, 0.1 to 75 wt%, 0.1 to 50 wt%, 1 to 99.9 wt%, 1 to 90 wt%, 1 to 75 wt%, 1 to 50 wt%, 5 to 99.9 wt% %, 5 to 90 wt%, 5 to 75 wt%, 5 to 50 wt%, 10 to 99.9 wt%, 10 to 90 wt%, 10 to
  • the pharmaceutical composition or food composition may include humans, primates such as monkeys, rodents such as mice, rats, rabbits, mammals, chickens, ducks, geese, including other dogs, cats, cows, pigs, sheep, horses, goats, etc. It may be administered to a subject selected from vertebrates such as birds, snakes, lizards, turtles, crocodiles, and the like, including reptiles, amphibians, and fish.
  • the mode of administration of the pharmaceutical composition may be any mode commonly used, such as oral administration, or intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, lesion site (e.g., muscle increase and/or muscle reduction inhibition It may be administered by a route of parenteral administration such as topical administration or intraperitoneal injection).
  • the pharmaceutical composition may be for oral administration, but is not limited thereto.
  • the pharmaceutical composition may be administered in a pharmaceutically effective amount.
  • the dosage of the pharmaceutical composition is variously prescribed depending on factors such as formulation method, administration mode, patient's age, weight, sex, pathological condition, food, administration time, administration interval, route of administration, excretion rate and response sensitivity. Can be.
  • the dosage may vary depending on the patient's age, weight, sex, dosage form, health condition, and degree of disease, and may be dividedly administered once a day or several times a day at regular time intervals according to the judgment of a doctor or pharmacist.
  • the one-time or daily dosage of the pharmaceutical composition is 0.001 to 10000 mg/kg, specifically, 0.01 to 10000 mg/kg, 0.01 to 5000 mg/kg, 0.01 to 10000 mg/kg, based on the solid content of the active ingredient (excess extract).
  • the one-time or daily dosage may be formulated as a single formulation in a unit dosage form, formulated in an appropriate amount, or prepared by incorporating into a multi-dose container.
  • the above dosage is an example of an average case, and the dosage may be high or low depending on individual differences.
  • Each of the pharmaceutical compositions can be formulated and used in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, or parenteral dosage forms in the form of sterile injectable solutions according to a conventional method. have.
  • the pharmaceutical composition is generally selected from the group consisting of a pharmaceutical and/or physiologically acceptable carrier, excipient, and diluent selected in consideration of the mode of administration and standard pharmaceutical practice. It may be administered in combination with one or more adjuvants.
  • the pharmaceutically and/or physiologically acceptable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, It may contain one or more selected from the group consisting of cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. However, it is not limited thereto, and may be any carrier commonly used in the pharmaceutical field.
  • the pharmaceutical and/or physiologically acceptable diluent and/or excipient is selected from the group consisting of all fillers, extenders, binders, wetting agents, disintegrants, lubricants, surfactants, etc. that are commonly used in the appropriate formulation of pharmaceutical compositions. There may be more than one type.
  • the excipient is at least one or more substances for formulation of such solid preparations, such as starch, calcium carbonate , Sucrose (Sucrose), lactose (Lactose), it may be one or more selected from the group consisting of gelatin.
  • lubricants such as magnesium stearate and talc may also be used.
  • formulation of liquid formulations for oral administration such as suspensions, liquid solutions, emulsions, syrups, etc.
  • at least one selected from the group consisting of water, liquid paraffin, etc., which are commonly used simple diluents may be used.
  • Various commonly used excipients for example, wetting agents, sweetening agents, fragrances, and/or preservatives may be included, but are not limited thereto.
  • the pharmaceutical composition may be in the form of a tablet containing starch or lactose, or in the form of a capsule containing an appropriate excipient, or in the form of an elixir or suspension containing a chemical agent to taste or color. It can be administered intranasally or sublingually.
  • Such liquid formulations can be used as suspensions (e.g., methylcellulose, semisynthetic glycerides such as Witepsol, or a mixture of PEG-6 esters with Apricot kernel oil or PEG-8 and caprylic/capric.
  • a mixture of glycerides, such as a mixture of glycerides) may be formulated with a pharmaceutically acceptable additive, but is not limited thereto.
  • the term "food” refers to an edible natural product or processed product containing one or more nutrients, and as a general meaning, various general foods, health functional foods, beverages, food additives, and It may be used to mean one or more selected from the group consisting of beverage additives and the like.
  • the term “food composition” may mean a combination of ingredients for preparing the food product.
  • the content of the herbal ingredient in the food composition can be appropriately adjusted according to the form and purpose of food use, for example, 0.00001 to 99.9% by weight, 0.0001 to 99.9% by weight, 0.001 to 99.9% by weight, or 0.001 to It may be 50% by weight, but is not limited thereto.
  • the'subject' to which the herbal active ingredient is administered is a mammal including humans, primates such as monkeys, rodents such as mice, rats, rabbits, and other dogs, cats, cows, pigs, sheep, horses, goats, etc. ,
  • An individual selected from vertebrates such as reptiles, amphibians, and fish, including birds, snakes, lizards, turtles, crocodiles, etc., including chickens, ducks, geese, etc., cells, tissues, or cell cultures isolated from the individual Etc.
  • 'muscle increase' may mean that the mass, volume, and/or density of skeletal muscle cells or skeletal muscle is increased compared to before administration of the excess (Amomum Tsaoko) extract.
  • 'muscle cells refers to cells constituting the muscle of mammals including humans, and may mean a myocyte, a myotube or myotube, a myotube, or both.
  • 'Muscle cell differentiation' may refer to the generation of muscle cells (myoblasts, myotubes, and/or muscle fibers) from myoblasts, or a series of processes accompanying it.
  • the media composition for differentiation of muscle cells may be one in which an extract of excess (Amomum Tsaoko) is additionally added to a media for differentiation of muscle cells that are commonly used.
  • the amount of the excess (Amomum Tsaoko) extract added may be 0.1 to 90% by weight, 0.1 to 75% by weight, 0.1 to 50% by weight, or 0.1 to 25% by weight, based on the total weight of the medium, but is not limited thereto.
  • the pharmaceutical composition and food composition comprising the excess (Amomum Tsaoko) extract provided herein can be effectively applied to the prevention, treatment, and/or improvement of pathological conditions associated with muscle reduction by promoting muscle differentiation. have.
  • 1 is a photomicrograph showing the differentiation effect of C2C12 cells of the ethanol extract of excess fruit.
  • Figure 2 is a result showing the results of Western blot testing according to the ethanol concentration (100%, 70%) AKT and mTOR phosphorylation degree when the excess fruit ethanol extract treatment.
  • Figure 3 is a graph showing the relative value of the degree of proliferation of C2C12 cells (100%) of the control group (untreated group) when the ethanol concentration (100%, 70%, 50%) extract and hot water extract are treated .
  • FIG. 4 is a graph showing the effect of excess 70% ethanol extract and hot water extract on PGC-1 ⁇ , GLUT-4, Creatine kinase, and ATP.
  • 5 is a fluorescence image showing cells by immunostaining techniques using MHC when treated with excess hot water extract.
  • 6 is a graph showing differentiation/regeneration and fusion index by measuring the number and diameter of nuclei per myotube of cells treated with excess hot water extract.
  • mitochondrial active oxygen mitochondrial active oxygen
  • Figure 8 shows the body weight (left), body weight change (center), and front shin muscle (TA muscle weight (mg)/body weight) at the time of administration of excess hot water extract (CTX+excess) to mice (CTX) in which muscle damage was induced by cardiotoxin administration.
  • CTX excess hot water extract
  • CTX+ NC water administration group
  • CK creatine kinase
  • 10 is a graph showing the gene expression level related to energy supply/recovery of muscle-injured mice to which excess hot water extract was administered compared with the water-administered group.
  • Figure 11 is a graph showing the quantification of the results showing the energy supply / recovery-related protein expression of muscle injured mice administered with excess hot water extract.
  • the fruit of the excess ( Amomum Tsaoko ) is prepared as dried (purchased at Kyungdong Market), pulverized, and then 10 times the volume of alcohol (98% to 100% (v)) based on the weight of the excess fruit in the crushed dry excess fruit.
  • /v) ethanol hereinafter referred to as "100% (v/v) ethanol”
  • 70% (v/v) ethanol or 50% (v/v) ethanol was added, followed by reflux extraction at 70 to 80°C for 5 hours
  • 100% (v/v) ethanol extract, 70% (v/v) ethanol extract, and 50% (v/v) ethanol extract which are ethanol extracts of excess fruit, were prepared, respectively, and concentrated under reduced pressure and frozen.
  • Samples of powder were prepared by precursor (hereinafter referred to as "100% (v/v) ethanol extract", “70% (v/v) ethanol extract”, and "50% (v/v) ethanol extract” respectively being).
  • Fruits of excess ( Amomum Tsaoko ) are prepared as dried (purchased at Kyungdong Market), pulverized, and then dried at 90 to 100°C using 10 volume times of water based on the weight of the excess fruit to the pulverized dried excess fruit. Extracted by reflux extraction for 5 hours to prepare an excess hot water extract.
  • the effect on myocyte differentiation was tested using the excess ethanol extract (100% (v/v) ethanol extract) extracted by the reflux extraction method in Example 1.1.
  • DM differentiation medium
  • DMEM Gibco
  • HS horse serum
  • ATCC® CRL-1772 TM was inoculated in an amount of 1*10 4 cells/96well, incubated for 24 to 72 hours at 37°C and 5% CO2 conditions, and the nuclei of the cells were observed under a microscope at 72 hours. Three or more overlapping parts were observed.
  • growth media Gibth media; GM; DMEM (Gibco), 1% Penicillin/streptomycin, 10% FBS
  • differentiation media Differentiation media; DM; DMEM (Gibco), 1% Penicillin/ streptomycin, 2% HS
  • FIG. 1 The results observed with the microscope are shown in FIG. 1. As shown in FIG. 1, when the excess 100% (v/v) ethanol extract was added to the DM medium and used, compared to the case of using GM or DM alone, the effect of increasing myocyte differentiation was remarkable.
  • the excess ethanol extract (100% (v/v) ethanol extract and 70% (v/v) extract) extracted by the reflux extraction method in Example 1.1 was used as a serum-free medium (Serum free).
  • Serum free media SM; DMEM (Gibco), 1% Penicillin/streptomycin
  • differentiation media Differentiation media; DM; DMEM (Gibco), 1% Penicillin/streptomycin, 2% HS
  • Ethanol extract (100% (v/v) ethanol) was added in an amount of 50 ug/ml to 10 ml of a culture medium prepared by inoculating C2C12 cell line (ATCC® CRL-1772 TM ) in a 100 mm dish with 80% confluence, and 37°C And incubation for 24 hours in 5% CO2 conditions, and Western blot was performed using an anti-p-AKT antibody and an anti-p-mTOR antibody (Cell signaling, USA) to measure p-AKT and p-mTOR, respectively. I did.
  • serum-free media serum free media
  • SM serum free media
  • DMEM DMEM
  • differentiation media Differentiation media
  • DM DMEM (Gibco), 1% Penicillin/streptomycin, 2% HS
  • a C2C12 cell line (ATCC® CRL-1772 TM ) was added to 200 ul of a culture medium prepared by adding the extract in an amount of 50 ug/ml, respectively, to serum free media (SM; DMEM (Gibco) 1% Penicillin/streptomycin). Inoculated in an amount of 1*10 4 cells/96well, cultured for 24 hours at 37°C and 5% CO2 conditions, and MTT assay was performed at 24 hours to measure the degree of cell proliferation. For comparison, the same test was performed by culturing the C2C12 cell line in the same manner in a serum-free medium to which the sample was not treated (untreated group; indicated by SM).
  • SM serum free media
  • MTT assay was performed at 24 hours to measure the degree of cell proliferation.
  • the same test was performed by culturing the C2C12 cell line in the same manner in a serum-free medium to which the sample was not treated (untreated group; indicated by SM).
  • FIG. 3 is an excess ethanol extract 100% (v / v) ethanol extract (100% EtOH), 70% (v / v) ethanol extract (70% EtOH), 50% (v / v) ethanol extract (50% EtOH) ), and the cell proliferation effect of the hot water extract (water), all of the four excess extracts showed superior C2C12 cell proliferation effect compared to the control (SM), and in particular, in the 70% (v/v) ethanol extract About 35%, and more than about 53% in the hot water extract, the proliferation effect of C2C12 cells was confirmed.
  • SM control
  • the differentiation media (Differentiation media; DM; DMEM (Gibco), 1% Penicillin/streptomycin, 2% HS) in excess hot water extract (DW) and excess ethanol extract (70% (v/v) ethanol; EtOH 70%) ) was added in an amount of 50 ug/ml to 10 ml of the prepared culture medium, inoculated with a C2C12 cell line (ATCC® CRL-1772 TM ) in a 100 mm dish at 80% confluence, and cultured for 24 hours at 37°C and 5% CO2 conditions.
  • DM Differentiation media
  • DMEM Gibco
  • 1% Penicillin/streptomycin 2% HS
  • ethanol extract 70% (v/v) ethanol; EtOH 70%
  • Fig. 4 shows the obtained results.
  • both the excess ethanol extract (EtOH 70%) and the hot water extract, compared to the control (excess extract untreated group; use only medium) the levels of PGC-1 ⁇ , GLUT-4, Creatine kinase, and ATP in myocytes was significantly increased, and in particular, the hot water extract showed a higher level of increase compared to the ethanol extract.
  • Example 1.2 in order to investigate the myotube growth enhancing effect of the excess extract, 5 ug/ml of the excess hot water extract prepared in Example 1.2 was treated to induce differentiation of C2C12 myoblasts for 48 hours.
  • the formed C2C12 myotubes were fixed with 4% (v/v) paraformaldehyde, permeabilized with 0.5% (v/v) Triton X-100, and reacted with MHC antibodies for 24 hours. Then, fluorescent staining was performed with a GFP-conjugated antibody.
  • DAPI (4',6-diamidino-2-phenylindole) was used to stain the nuclei.
  • the fluorescence image obtained by observing the MHC-positive cells obtained as a result of the test with a fluorescence microscope is shown in FIG. 5, and the distribution of MHC-positive cells according to the number of nuclei in the culture is shown in FIG. 5 and 6, when the excess extract was treated, the number of MHC-positive cells increased compared to the control (DMSO treatment) (FIG. 5), and the number of nuclei in MHC-positive cells was 6 or more. The ratio increased significantly (Fig. 6).
  • ROS mitochondrial active oxygen
  • the level of mitochondrial active oxygen upon treatment with excess extract was measured by the Mito Tracker ® red test method.
  • 100 nM MitoTracker Red (Invitrogen, USA) was reacted to C2C12 myotubes at 37° C. for 30 minutes, and the myotubes were lysed to a fluorescence spectrometer. It was measured as.
  • FIG. 7 shows the mitochondrial reactive oxygen levels when treated with excess extract as a relative value to the control group (DMSO treatment group). As shown in FIG. 7, it can be seen that when the excess extract is treated, the level of mitochondrial active oxygen is significantly reduced compared to the control. These results show that the excess extract has antioxidant activity against mitochondria and can contribute to enhancing the function.
  • test was designed as follows.
  • CX cardiotoxin
  • the excess hot water extract prepared in Example 1.2 was administered with negative water for 21 days, and water was changed every two days.
  • the excess hot water extract was diluted to a concentration of 2 ug/ml and used, and negative water was administered at a dose of 1.6 to 2.8 mg/kg.
  • mice were divided into three groups as follows:
  • NC No injury + Water
  • CTX injury + Water (CTX+NC) (muscular injury water administration group; 5 animals)
  • CTX administered to mice inducing muscle damage were administered negatively for 21 days;
  • CTX injury + excess extract (CTX + excess) (Excess muscle damage extract administration group; 5 mice)
  • the body weight (day 0 and day 21) of the mice prepared in Example 8.1 was measured, and the amount of body weight change (body weight on day 21-body weight on day 0) was calculated.
  • Fig. 8 shows the obtained results.
  • the body weight of the muscle damage excess extract-administered group increased compared to the normal water-administered group, and unlike the muscle-damaged water-administered group, the muscle damage excess extract-administered group had no significant change in body weight.
  • the TA/BW value of the muscle damage excess extract group was significantly increased compared to the normal water administration group and the muscle damage water administration group.
  • the activity of creatine kinase (CK) in the normal water administration group, the muscle injury water administration group, and the muscle damage excess extract administration group prepared in Example 8.1 was measured, and the effect of improving muscle fatigue according to the administration of the excess extract was confirmed.
  • the OD value was measured every 1 minute by an enzymatic assay, for a total of 15 minutes.
  • Fig. 9 shows the obtained results.
  • the creatine kinase activity of the muscle damage excess extract administration group was significantly lower than that of the normal water administration group and the muscle damage water administration group. Since creatine kinase activity is a representative marker that can confirm muscle fatigue, the above results demonstrate the effect of improving muscle fatigue of the excess extract.
  • RNA from TA miscle tissue obtained in Example 8.2 was extracted using QIAzol Lysis reagent RNeasy Lipid Tissue Mini Kit (Qiagen, USA), and 1 ⁇ g RNA was added to oligo-dT (oligo-dT) and superscript II reverse transcriptase. (Invitrogen, USA) cDNA was synthesized. Gene expression of the synthesized 1000ng cDNA was compared through quantitative real-time PCR amplification. Data were obtained using the comparative-cycle threshold method and expressed as fold change, and beta-actin was used as a control in the comparative CT method.
  • the primers used for the qPCR are summarized in Table 2 below.
  • the obtained expression levels (mRNA levels) of PGC1 ⁇ (PGC1alpha), GLUT4, and PPAR ⁇ (PPARgamma) are shown in FIG. 10 as relative values to the normal water administration group.
  • the expression levels of PGC1 ⁇ , GLUT4, and PPAR ⁇ in the muscle damage excess extract administration group were significantly higher than that of the normal water administration group and the muscle damage water administration group.
  • the protein concentration related to energy supply and recovery in the mice prepared in Example 8.1 was measured.
  • PGC1 ⁇ (Millipore, USA) was used as the energy supply and recovery-related protein, and the protein concentration was measured by Western blot.
  • Tissue protein extraction (Thermo, USA) was added to the TA miscle tissue obtained in Example 8.2, and the tissue was crushed using a tissue lyser (Qiagen). After stabilization for 10 minutes and centrifugation for 10 minutes at 14000 rpm, a supernatant was obtained, western blot was performed using an anti-PGC1 ⁇ antibody, and protein was quantified.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne l'utilisation d'un ingrédient de type herbe médicinale pour prévenir, atténuer et/ou traiter des maladies liées à la sarcopénie et, plus particulièrement, l'invention concerne une composition pharmaceutique pour prévenir et/ou traiter des maladies liées à la sarcopénie ou une composition alimentaire pour prévenir et/ou atténuer des maladies liées à la sarcopénie, comprenant chacune un extrait d'Amomum tsaoko.
PCT/KR2020/010685 2019-08-16 2020-08-12 Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie WO2021033995A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190100471 2019-08-16
KR10-2019-0100471 2019-08-16

Publications (1)

Publication Number Publication Date
WO2021033995A1 true WO2021033995A1 (fr) 2021-02-25

Family

ID=74660551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/010685 WO2021033995A1 (fr) 2019-08-16 2020-08-12 Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie

Country Status (2)

Country Link
KR (1) KR102444282B1 (fr)
WO (1) WO2021033995A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117243126A (zh) * 2023-11-20 2023-12-19 云南省农业科学院药用植物研究所 草果种质资源离体保存方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140113199A (ko) * 2013-03-15 2014-09-24 단국대학교 산학협력단 초과 추출물을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물
JP2015202066A (ja) * 2014-04-11 2015-11-16 有限会社中垣技術士事務所 筋芽細胞分化促進食品及びその製法
KR20160083610A (ko) * 2014-12-31 2016-07-12 단국대학교 천안캠퍼스 산학협력단 초과(Amomi Tsao-ko)로부터 분리된 화합물 및 이의 항염 용도
KR20160146980A (ko) * 2014-04-28 2016-12-21 산토리 홀딩스 가부시키가이샤 퀘르세틴 배당체를 함유하는 근위축 억제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140113199A (ko) * 2013-03-15 2014-09-24 단국대학교 산학협력단 초과 추출물을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물
JP2015202066A (ja) * 2014-04-11 2015-11-16 有限会社中垣技術士事務所 筋芽細胞分化促進食品及びその製法
KR20160146980A (ko) * 2014-04-28 2016-12-21 산토리 홀딩스 가부시키가이샤 퀘르세틴 배당체를 함유하는 근위축 억제제
KR20160083610A (ko) * 2014-12-31 2016-07-12 단국대학교 천안캠퍼스 산학협력단 초과(Amomi Tsao-ko)로부터 분리된 화합물 및 이의 항염 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIAN-TIAN ZHANG, CHUAN-LI LU, JIAN-GUO JIANG: "Bioactivity evaluation of ingredients identified from the fruits of Amomum tsaoko Crevost et Lemaire, a Chinese spice", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 5, no. 8, 1 August 2014 (2014-08-01), GB, pages 1747 - 1754, XP055422573, ISSN: 2042-6496, DOI: 10.1039/C4FO00169A *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117243126A (zh) * 2023-11-20 2023-12-19 云南省农业科学院药用植物研究所 草果种质资源离体保存方法及应用
CN117243126B (zh) * 2023-11-20 2024-01-23 云南省农业科学院药用植物研究所 草果种质资源离体保存方法及应用

Also Published As

Publication number Publication date
KR20210020818A (ko) 2021-02-24
KR102444282B1 (ko) 2022-09-16

Similar Documents

Publication Publication Date Title
WO2017078499A2 (fr) Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase
WO2019226015A1 (fr) Composition pour favoriser la myogenèse, contenant un extrait de ginseng traité
WO2013176471A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par stat-3, contenant un extrait ou une fraction de salvia plebeia r. br. en tant que principe actif
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2023080552A1 (fr) Peptide ayant des activités physiologiques et son utilisation
KR20200145717A (ko) 근육질환 예방 또는 치료용 조성물
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2023027317A1 (fr) Composition pour le traitement de maladies liées à la perte musculaire comprenant des exosomes dérivés de cellules souches mésenchymateuses de l'amygdale
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2022015033A1 (fr) Composition pour le traitement d'une maladie cérébrale comprenant pediococcus inopinatus ou des vésicules extracellulaires dérivées de celui-ci en tant que substance active
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2016144125A2 (fr) Nouvelle utilisation d'extrait de solanum nigrum l.
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
WO2014051398A1 (fr) Composition pharmaceutique comprenant de l'acécaïnide ou un dérivé de celui-ci pour la prévention ou le traitement de maladies associées à une faiblesse musculaire
WO2015108372A1 (fr) Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci
WO2019098568A2 (fr) Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica
WO2020256397A1 (fr) Composition pour la prévention ou le traitement de maladies musculaires, contenant, en tant que principe actif, un extrait de glycyrrhiza uralensis ou un composé isolé dans celui-ci
WO2021075818A1 (fr) Extrait de lichen d'antarctique umbilicaria antarctica ayant une activité anti-inflammatoire, et composition contenant celui-ci
WO2023085820A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies musculaires
WO2023003193A1 (fr) Composition comprenant de la paeoniflorine pour la prévention ou le traitement de la cachexie et de la perte musculaire
WO2023080553A1 (fr) Peptide ayant une activité physiologique et son utilisation
WO2023027540A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc
WO2011059294A2 (fr) Composition anticancéreuse améliorant l'immunité contenant des alcaloïdes de type morphinane au titre de principes actifs
WO2023229282A1 (fr) Composition pour prévenir, traiter ou améliorer des maladies métaboliques, comprenant une souche de lactobacillus kunkeei nchbl-003 ou un milieu de culture associé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20853856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20853856

Country of ref document: EP

Kind code of ref document: A1